BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, announced today the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3™, which received FDA clearance last month. Butterfly iQ3 is powered by the Company’s most advanced semiconductor chip with a data transfer rate that is double that of its predecessor. The result is unparalleled image quality and faster micro-beamforming for advanced 3D capabilities: iQ Slice™ and iQ Fan™.

“Butterfly iQ3 is a pivotal moment in Butterfly’s trajectory, further validating the company’s initial hypothesis that semiconductor-based digital ultrasound is not only viable, but the future of all ultrasound,” said Joseph DeVivo, Butterfly Network’s President, Chief Executive Officer, and Board Chairman. “With the introduction of iQ3, we’re witnessing a paradigm shift in ultrasound. iQ3 sets a new standard where digital image quality matches that of traditional handheld devices, and even certain carts. This device will attract more seasoned POCUS experts to choose Butterfly and support new learners to gain confidence and competency through artificial intelligence and advanced imaging tools.”

Unparalleled image quality.
Butterfly iQ3 brings best-in-class, high-resolution image quality with twice the processing power compared to Butterfly iQ+ and a novel “no focus” rubber lens, enabling providers to intuitively identify anatomy, observe small structures, and ultimately, make more confident diagnostic decisions. In a blind survey distributed by third-party vendor, Intellisurvey, 475 clinicians across more than eight specialties compared Butterfly iQ3 images to GE Vscan Air™ CL, with the majority across all categories ranking iQ3’s overall image quality better than that of GE Vscan Air™ CL.*

"Healthcare is at a cornerstone in the adoption of point-of-care ultrasound. Bedside ultrasound has the potential to vastly increase the information available to clinicians for proper assessment, intervention, and prevention of cardiovascular diseases and other conditions across the human body," said Partho Sengupta, MD, Henry Rutgers Professor and Chief of Cardiology at Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital. "I use Butterfly in my clinical practice and in clinical research. The introduction of Butterfly iQ3 includes a focus on higher precision capabilities for cardiovascular point-of-care ultrasound applications to inform complex decisions. In my early experience, I found that the enhancements in visualization technology and artificial intelligence, as well as image quality will greatly assist health care professionals in our efforts to continually improve outcomes for our patients.”

Ultrasound Homepage